$1,600,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed, from Q1 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Unmet medical need in acute pain; H.R.1227/S.475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease. Issues related to corporate tax reform. Education about non-opioid pain therapies and patient access to non-opioid medicines, education on alternative funding programs, education on the Million Veteran Program at the VA. Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, HELP Copays Act (S.864); Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments."
You can find more data on corporate lobbying on Quiver Quantitative.
VRTX Congressional Stock Trading
Members of Congress have traded $VRTX stock 4 times in the past 6 months. Of those trades, 2 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $VRTX stock by members of Congress over the last 6 months:
- REPRESENTATIVE BYRON DONALDS has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 03/20.
- REPRESENTATIVE JEFFERSON SHREVE has traded it 2 times. They made 2 purchases worth up to $100,000 on 03/13, 02/24 and 0 sales.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
VRTX Insider Trading Activity
VRTX insiders have traded $VRTX stock on the open market 21 times in the past 6 months. Of those trades, 0 have been purchases and 21 have been sales.
Here’s a breakdown of recent trading of $VRTX stock by insiders over the last 6 months:
- RESHMA KEWALRAMANI (CEO & President) sold 15,198 shares for an estimated $7,826,970
- DAVID ALTSHULER (EVP, Chief Scientific Officer) has made 0 purchases and 7 sales selling 12,939 shares for an estimated $6,405,364.
- OURANIA TATSIS (EVP, Chief Reg. & Quality Off.) has made 0 purchases and 4 sales selling 7,854 shares for an estimated $3,844,667.
- EDWARD MORROW III ATKINSON (EVP, Chief Technical Ops. Off.) has made 0 purchases and 3 sales selling 6,164 shares for an estimated $2,912,812.
- JONATHAN BILLER (EVP and Chief Legal Officer) has made 0 purchases and 2 sales selling 5,090 shares for an estimated $2,332,768.
- CHARLES F JR WAGNER (EVP & Chief Financial Officer) sold 3,298 shares for an estimated $1,649,000
- KRISTEN AMBROSE (SVP & Chief Accounting Officer) has made 0 purchases and 3 sales selling 2,931 shares for an estimated $1,363,231.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
VRTX Hedge Fund Activity
We have seen 687 institutional investors add shares of VRTX stock to their portfolio, and 741 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ALLIANCEBERNSTEIN L.P. removed 3,452,747 shares (-46.8%) from their portfolio in Q4 2024, for an estimated $1,390,421,216
- PARNASSUS INVESTMENTS, LLC added 1,815,950 shares (+inf%) to their portfolio in Q4 2024, for an estimated $731,283,065
- CAPITAL WORLD INVESTORS added 1,514,993 shares (+5.7%) to their portfolio in Q4 2024, for an estimated $610,087,681
- CAPITAL RESEARCH GLOBAL INVESTORS added 1,426,746 shares (+15.8%) to their portfolio in Q4 2024, for an estimated $574,550,614
- EDGEWOOD MANAGEMENT LLC added 1,410,238 shares (+91.2%) to their portfolio in Q4 2024, for an estimated $567,902,842
- FMR LLC removed 1,305,967 shares (-12.4%) from their portfolio in Q4 2024, for an estimated $525,912,910
- JENNISON ASSOCIATES LLC removed 1,232,624 shares (-22.2%) from their portfolio in Q4 2024, for an estimated $496,377,684
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
VRTX Analyst Ratings
Wall Street analysts have issued reports on $VRTX in the last several months. We have seen 5 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- China Renaissance Securities (US) Inc. issued a "Positive" rating on 02/10/2025
- BMO Capital issued a "Outperform" rating on 01/31/2025
- H.C. Wainwright issued a "Buy" rating on 01/31/2025
- Citigroup issued a "Buy" rating on 11/13/2024
- Canaccord Genuity issued a "Sell" rating on 10/22/2024
- Goldman Sachs issued a "Buy" rating on 10/21/2024
To track analyst ratings and price targets for VRTX, check out Quiver Quantitative's $VRTX forecast page.
VRTX Price Targets
Multiple analysts have issued price targets for $VRTX recently. We have seen 9 analysts offer price targets for $VRTX in the last 6 months, with a median target of $540.0.
Here are some recent targets:
- Evan Seigerman from BMO Capital set a target price of $545.0 on 01/31/2025
- Mohit Bansal from Wells Fargo set a target price of $460.0 on 01/30/2025
- Terence Flynn from Morgan Stanley set a target price of $456.0 on 01/10/2025
- Brian Abrahams from RBC Capital set a target price of $400.0 on 12/19/2024
- Michael Yee from Jefferies set a target price of $550.0 on 12/09/2024
- Hartaj Singh from Oppenheimer set a target price of $540.0 on 11/05/2024
- Whitney Ijem from Canaccord Genuity set a target price of $361.0 on 10/22/2024
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
